Qvatic SR 50mg, 100mg, 200mg, 300mg and 400 mg

Qvatic SR 50mg, 100mg, 200mg, 300mg and 400 mg

Quetiapine Fumarate Sustained-Release

Qvatic SR SR 50mg, 100mg, 200mg, 300mg and 400 mg (Quetiapine Fumarate Sustained-Release) contains the antipsychotic salt quetiapine fumarate in a sustained-release matrix that delivers the medicine gradually over 24 hours. Quetiapine modulates activity at dopamine (D₂) and serotonin (5-HT₂) receptors in brain circuits that govern perception, mood and sleep. This re-balancing reduces hallucinations and delusions, calms mania and agitation, and helps relieve depressive symptoms in bipolar disorder. Because the SR tablet releases quetiapine slowly, a single evening dose gives steady control with fewer peaks and troughs than immediate-release tablets

Qvatic SR (quetiapine fumarate) is prescribed for schizophrenia and bipolar disorder (manic/mixed episodes and bipolar depression). Where local guidance allows, it may also be used as adjunct therapy in major depressive disorder when an add-on antipsychotic is appropriate.

All five strengths 50 mg, 100 mg, 200 mg, 300 mg and 400 mg—exist to allow precise titration. Treatment always starts low and is increased by your clinician over several days to a dose that controls symptoms with good tolerability. For schizophrenia, adults commonly begin in the evening and increase toward a usual effective range of 400–800 mg once daily. For acute mania in bipolar disorder, the dose is built up quickly over the first two days, then adjusted within 400–800 mg once daily according to response. For bipolar depression, many patients respond to 300 mg once nightly after a short four-day up-titration; some require 200–300 mg. When used as adjunct treatment in major depression, a maintenance dose of 150–300 mg nightly is typical if your doctor considers it suitable. If you are switching from immediate-release quetiapine, your prescriber usually converts you to approximately the same total daily dose given once nightly with Qvatic SR and then fine-tunes as needed. In hepatic impairment and in older adults, the starting dose is lower (for example 50 mg nightly) with slower 50-mg increments. Pediatric use should follow a specialist’s direction only.

Administration: Take Qvatic SR once daily in the evening, at about the same time each night. Swallow the tablet whole with water; do not split, crush or chew it, as that destroys the sustained-release design. Try to take it consistently with or without food as advised by your clinician.

Storage: Store in a cool, dry place away from moisture and direct sunlight. Keep out of reach of children.

Common Side Effects: Many patients experience sleepiness, dizziness, dry mouth, constipation, increased appetite and weight, light-headedness on standing, and small, usually reversible changes in blood sugar or lipids. Some notice restlessness (akathisia) or mild tremor. Contact your doctor promptly if you develop a fast or irregular heartbeat, fainting, severe constipation, yellowing of the eyes/skin, seizures, a persistent fever with muscle stiffness and confusion (possible neuroleptic malignant syndrome), or any thoughts of self-harm.

Drug Warnings: Before taking Qvatic SR (quetiapine fumarate), inform your doctor if you have heart disease or a family history of long QT or sudden cardiac death, low blood pressure or a tendency to faint, diabetes or high cholesterol/triglycerides, liver disease, seizure disorders, glaucoma or urinary retention, thyroid problems, cataracts, or a history of depression or suicidal thoughts. Use in elderly patients with dementia-related psychosis is associated with increased mortality and stroke risk and is generally not approved—follow your clinician’s guidance closely. Avoid taking Qvatic SR with other sedating medicines unless advised, as combined effects can impair alertness and coordination.

Drug–Drug Interactions: Quetiapine is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors for example ketoconazole, itraconazole, clarithromycin, certain HIV protease inhibitors and grapefruit products can markedly raise blood levels; your prescriber may avoid these or lower your dose. Strong CYP3A4 inducers such as carbamazepine, phenytoin and rifampicin can lower quetiapine levels and reduce efficacy; your doctor may switch interacting drugs or adjust your dose. Additive sedation occurs with alcohol, benzodiazepines, opioids, sedating antihistamines, sleep medicines and some antipsychotics. Use caution with medicines that prolong the QT interval (certain antiarrhythmics, macrolides, fluoroquinolones and others) and with antihypertensives, which may enhance postural dizziness.

Drug–Food Interactions: Take Qvatic SR consistently as directed; your doctor may prefer evening dosing with a light meal. Avoid grapefruit or grapefruit juice, which can increase quetiapine exposure. Limit alcohol, as it increases sleepiness and slows reaction time.

Drug–Disease Interactions: Patients with liver impairment require lower starting doses and careful titration. Those with diabetes/metabolic syndrome need regular monitoring of weight, fasting glucose and lipids. People with heart-rhythm abnormalities, seizures, glaucoma or prostate enlargement, or severe constipation should discuss risks and monitoring plans with their clinician. Always share your full medical history to ensure safe and effective use of Qvatic SR 50/100/200/300/400 mg (quetiapine fumarate sustained-release).